Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1995 Sep;4(5):331–338. doi: 10.1155/S0962935195000536

Tissue eosinophilia induced by recombinant human interleukin-5 in the hamster cheek pouch membrane

M Minnicozzi 1,2,✉, W N Durán 2,3, D Kim 3, G J Gleich 4, J Wagner 4, R W Egan 1,3
PMCID: PMC2365657  PMID: 18475660

Abstract

Interleukin-5 (IL-5) is a cytokine that preferentially effects the development and function of eosinophils, and is considered important in the pathophysiology of allergic inflammation. In this study, we evaluated the ability of recombinant human IL-5 (rHu IL-5) to promote tissue eosinophilia and the importance of this eosinophilia to pathological alterations in vascular function. Repetitive subcutaneous administration for 18 days of rHu IL-5 resulted in a 7-fold increase in the number of eosinophils found in the ipsilateral hamster cheek pouch membrane. The contralateral cheek pouch membrane and peritoneum of these animals showed lesser but significant elevations in the number of eosinophils. In contrast, denatured rHu IL-5 did not elevate eosinophils in these tissues. Through the use of intravital microscopy and fluorometric analysis, rHu IL-5 treated hamster cheek pouch membranes were evaluated for alterations in microvascular permeability, using plasma clearance of FITC-dextran 150 as an index. Despite promoting a prominent tissue eosinophilia, the repetitive subcutaneous injections of rHu IL-5 did not alter the clearance of FITC-dextran 150. Topical application of rHu IL-5 to the cheek pouch, also, had no effect on the clearance of FITC-dextran 150. Immunofluorescence observations using an antibody to the granule protein, eosinophil peroxidase, indicated that the recruited cells had not degranulated. Our results support the importance of IL-5 in the recruitment of tissue eosinophils, but further stimulation is probably required to cause degranulation of these cells and the ensuing tissue damage.

Full Text

The Full Text of this article is available as a PDF (905.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abu-Ghazaleh R. I., Dunnette S. L., Loegering D. A., Checkel J. L., Kita H., Thomas L. L., Gleich G. J. Eosinophil granule proteins in peripheral blood granulocytes. J Leukoc Biol. 1992 Dec;52(6):611–618. doi: 10.1002/jlb.52.6.611. [DOI] [PubMed] [Google Scholar]
  2. Beasley R., Roche W. R., Roberts J. A., Holgate S. T. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis. 1989 Mar;139(3):806–817. doi: 10.1164/ajrccm/139.3.806. [DOI] [PubMed] [Google Scholar]
  3. Bekker A. Y., Ritter A. B., Duran W. N. Reduction of pressure in postcapillary venules induced by EPI-fluorescent illumination of FITC-dextrans. Microcirc Endothelium Lymphatics. 1986;3(5-6):411–423. [PubMed] [Google Scholar]
  4. Chihara J., Plumas J., Gruart V., Tavernier J., Prin L., Capron A., Capron M. Characterization of a receptor for interleukin 5 on human eosinophils: variable expression and induction by granulocyte/macrophage colony-stimulating factor. J Exp Med. 1990 Nov 1;172(5):1347–1351. doi: 10.1084/jem.172.5.1347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clutterbuck E. J., Hirst E. M., Sanderson C. J. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood. 1989 May 1;73(6):1504–1512. [PubMed] [Google Scholar]
  6. Coffman R. L., Seymour B. W., Hudak S., Jackson J., Rennick D. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science. 1989 Jul 21;245(4915):308–310. doi: 10.1126/science.2787531. [DOI] [PubMed] [Google Scholar]
  7. Dent L. A., Strath M., Mellor A. L., Sanderson C. J. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med. 1990 Nov 1;172(5):1425–1431. doi: 10.1084/jem.172.5.1425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dillon P. K., Durán W. N. Effect of platelet-activating factor on microvascular permselectivity: dose-response relations and pathways of action in the hamster cheek pouch microcirculation. Circ Res. 1988 Apr;62(4):732–740. doi: 10.1161/01.res.62.4.732. [DOI] [PubMed] [Google Scholar]
  9. Durán W. N., Dillon P. K. Acute microcirculatory effects of platelet-activating factor. J Lipid Mediat. 1990;2 (Suppl):S215–S227. [PubMed] [Google Scholar]
  10. Fabian I., Lass M., Kletter Y., Golde D. W. Differentiation and functional activity of human eosinophilic cells from an eosinophil HL-60 subline: response to recombinant hematopoietic growth factors. Blood. 1992 Aug 1;80(3):788–794. [PubMed] [Google Scholar]
  11. Fujisawa T., Abu-Ghazaleh R., Kita H., Sanderson C. J., Gleich G. J. Regulatory effect of cytokines on eosinophil degranulation. J Immunol. 1990 Jan 15;144(2):642–646. [PubMed] [Google Scholar]
  12. Ghiabi M., Gallagher G. T., Wong D. T. Eosinophils, tissue eosinophilia, and eosinophil-derived transforming growth factor alpha in hamster oral carcinogenesis. Cancer Res. 1992 Jan 15;52(2):389–393. [PubMed] [Google Scholar]
  13. Gulbenkian A. R., Egan R. W., Fernandez X., Jones H., Kreutner W., Kung T., Payvandi F., Sullivan L., Zurcher J. A., Watnick A. S. Interleukin-5 modulates eosinophil accumulation in allergic guinea pig lung. Am Rev Respir Dis. 1992 Jul;146(1):263–266. doi: 10.1164/ajrccm/146.1.263. [DOI] [PubMed] [Google Scholar]
  14. Hamann K. J., Barker R. L., Ten R. M., Gleich G. J. The molecular biology of eosinophil granule proteins. Int Arch Allergy Appl Immunol. 1991;94(1-4):202–209. doi: 10.1159/000235362. [DOI] [PubMed] [Google Scholar]
  15. Hodges M. K., Weller P. F., Gerard N. P., Ackerman S. J., Drazen J. M. Heterogeneity of leukotriene C4 production by eosinophils from asthmatic and from normal subjects. Am Rev Respir Dis. 1988 Oct;138(4):799–804. doi: 10.1164/ajrccm/138.4.799. [DOI] [PubMed] [Google Scholar]
  16. Ishizaka T., Saito H., Hatake K., Dvorak A. M., Leiferman K. M., Arai N., Ishizaka K. Preferential differentiation of inflammatory cells by recombinant human interleukins. Int Arch Allergy Appl Immunol. 1989;88(1-2):46–49. doi: 10.1159/000234746. [DOI] [PubMed] [Google Scholar]
  17. Kita H., Weiler D. A., Abu-Ghazaleh R., Sanderson C. J., Gleich G. J. Release of granule proteins from eosinophils cultured with IL-5. J Immunol. 1992 Jul 15;149(2):629–635. [PubMed] [Google Scholar]
  18. Lee T., Lenihan D. J., Malone B., Roddy L. L., Wasserman S. I. Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem. 1984 May 10;259(9):5526–5530. [PubMed] [Google Scholar]
  19. Leiferman K. M. Eosinophils in atopic dermatitis. Allergy. 1989;44 (Suppl 9):20–26. [PubMed] [Google Scholar]
  20. Lopez A. F., Sanderson C. J., Gamble J. R., Campbell H. D., Young I. G., Vadas M. A. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med. 1988 Jan 1;167(1):219–224. doi: 10.1084/jem.167.1.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mayhan W. G., Joyner W. L. The effect of altering the external calcium concentration and a calcium channel blocker, verapamil, on microvascular leaky sites and dextran clearance in the hamster cheek pouch. Microvasc Res. 1984 Sep;28(2):159–179. doi: 10.1016/0026-2862(84)90015-3. [DOI] [PubMed] [Google Scholar]
  22. McKenzie A. N., Ely B., Sanderson C. J. Mutated interleukin-5 monomers are biologically inactive. Mol Immunol. 1991 Jan-Feb;28(1-2):155–158. doi: 10.1016/0161-5890(91)90099-6. [DOI] [PubMed] [Google Scholar]
  23. Minnicozzi M., Durán W. N., Gleich G. J., Egan R. W. Eosinophil granule proteins increase microvascular macromolecular transport in the hamster cheek pouch. J Immunol. 1994 Sep 15;153(6):2664–2670. [PubMed] [Google Scholar]
  24. Ohnishi T., Kita H., Weiler D., Sur S., Sedgwick J. B., Calhoun W. J., Busse W. W., Abrams J. S., Gleich G. J. IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction. Am Rev Respir Dis. 1993 Apr;147(4):901–907. doi: 10.1164/ajrccm/147.4.901. [DOI] [PubMed] [Google Scholar]
  25. Ohnishi T., Sur S., Collins D. S., Fish J. E., Gleich G. J., Peters S. P. Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge. J Allergy Clin Immunol. 1993 Oct;92(4):607–615. doi: 10.1016/0091-6749(93)90085-t. [DOI] [PubMed] [Google Scholar]
  26. Rothenberg M. E., Petersen J., Stevens R. L., Silberstein D. S., McKenzie D. T., Austen K. F., Owen W. F., Jr IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. J Immunol. 1989 Oct 1;143(7):2311–2316. [PubMed] [Google Scholar]
  27. Sanderson C. J. Interleukin-5, eosinophils, and disease. Blood. 1992 Jun 15;79(12):3101–3109. [PubMed] [Google Scholar]
  28. Tomeo A. C., Egan R. W., Durán W. N. Priming interactions between platelet activating factor and histamine in the in vivo microcirculation. FASEB J. 1991 Oct;5(13):2850–2855. doi: 10.1096/fasebj.5.13.1655549. [DOI] [PubMed] [Google Scholar]
  29. Yamaguchi Y., Hayashi Y., Sugama Y., Miura Y., Kasahara T., Kitamura S., Torisu M., Mita S., Tominaga A., Takatsu K. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med. 1988 May 1;167(5):1737–1742. doi: 10.1084/jem.167.5.1737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Yamaguchi Y., Hayashi Y., Sugama Y., Miura Y., Kasahara T., Kitamura S., Torisu M., Mita S., Tominaga A., Takatsu K. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med. 1988 May 1;167(5):1737–1742. doi: 10.1084/jem.167.5.1737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Yamaguchi Y., Suda T., Ohta S., Tominaga K., Miura Y., Kasahara T. Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood. 1991 Nov 15;78(10):2542–2547. [PubMed] [Google Scholar]
  32. Yoshikawa S., Kayes S. G., Parker J. C. Eosinophils increase lung microvascular permeability via the peroxidase-hydrogen peroxide-halide system. Bronchoconstriction and vasoconstriction unaffected by eosinophil peroxidase inhibition. Am Rev Respir Dis. 1993 Apr;147(4):914–920. doi: 10.1164/ajrccm/147.4.914. [DOI] [PubMed] [Google Scholar]
  33. van Haelst Pisani C., Kovach J. S., Kita H., Leiferman K. M., Gleich G. J., Silver J. E., Dennin R., Abrams J. S. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood. 1991 Sep 15;78(6):1538–1544. [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES